Expert Cancer Panel: CML chronic phase T315I mutated s/p multiple lines of therapy

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Recorded on 10/9/2021

60-year-old male with chronic myelogenous leukemia (CML) chronic phase T315I mutated that has progressed through multiple lines of therapy.

Summary:
- For a transplant ineligible patient with CML and T315I mutation, who developed an arterial occlusive event while on ponatinib, and has suboptimal response to omacetaxine currently, the panel recommends novel BCR-ABL1 inhibitor asciminib, but if unable to obtain, lower dose ponatinib or ponatinib with addition of antiplatelet/anticoagulant agent would be reasonable with the understanding that the risk of another arterial occlusive event is present.


At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.

Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.

Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca

Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
Category
Oncology
Be the first to comment

Up Next